DAFTAR PUSTAKA

1. Jusuf A, Harryanto A, Syahruddin E, dkk. Kanker paru jenis karsinoma bukan sel kecil :
Pedoman nasional untuk diagnosis dan penatalaksanaan di Indonesia 2005.; edisi revisi.
Jakarta: PDPI; 2005 :1-14.
2. Survei Kesehatan Rumah Tangga 2002. Departemen Kesehatan Republik Indonesia.
Berger AM, Fall-Dickson JM. Oral complications. In: DeVita VT, Hellman S, Rosenberg
SA. Cancer: Principles and practice of oncology. 7th ed. Philadelphia, Pa: Lippincott
Williams & Wilkins; 2005: 2523-35. ^T^ibby et al. Cardiovascular complication of cancer
therapheutic agents. In: Zipes DP, Libby P, Brauwald E. Heart disease: A textbook of
cardiovascular medicine. 7th ed. Philadelphia, Saunders Elsevier Inc; 2005:2122-5. 5J)
Page R, Takimoto C. Principles of chemotherapy. In : Page R. Cancer management: A
multidiciplinary approach. 5^ ed. Philadelphia:Lange;2003:21-9.
6. Schimmel K, Richel D, Brink R, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer
Treatment Rev 2004;30:181-91.
7. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion D, et al. Cardiovascular
complication of cancer therapy : diagnosis, pathogenesis, and management. Circulation
2004;109:3122-31.
8. Horacek JM, Pudil R, Tichy M, Jebavy L, Zak P. Biochemical markers and assessment of
cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute
leukemia. Exp Oncol 2007;29(3):243-7.
9. Lenihan DJ. Massey MR, Baysinger KB, Adorno CL, Warneke CL, Seinert D. Superior
detection of cardiotoxicity during chemotherapy using biomarkers. Presented abstract in
the 11^ Annual Scientific Meeting Cardiology. HFSA S151.
10. Singal PK, Iliskovic N. Doxorubicine-induced cardiomyopathy. N Engl J Med
1998;339( 13):900-4.
11. Kruger A, Wojnowski L. Cardiotoxicity of anthracyclines- an unsolved problem. Dtsch
Arztebl 2006; 103(37):2393-7.
12. Shan K, Lincoff M, Young JB. Anthracycline-induced cardiotoxicity. Annals of Internal
Medicine. 1996;125:47-58
13. Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin induced congestive heart
failure. Ann Intern Med 1979;91:710-7.
14. Swain SM, Whaley PS, Ewer MS. Congestive heart failure in patients treated with
doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79.
15. Chanan A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity
from antineoplastic therapy. J Support Oncol 2004;2:251-66.
16. Schwartz RG, McKenzie WB, Alexander J. Congestive heart failure and left ventricular
dsfunction complicating doxorubicin therapy : seven year experience using serial
radionuclide angiocardiography. Am J Med 1987;82:1109-18.
17. Thomas L, Bellmount S, Christen MO. Cardiovascular and survival effects of sympatho-
inhibitors in adriamycin-induced cardiomyopathy in rats. Fundam Clin Pharmacol
2004;18:649-55.
18. Boucek RJ, Steele A, Miracle A. Effets of angiotensin converting enzyme inhibitor on
delayed onset doxorubicin induced cardiotoxicity. Cardiovasc Toxicol 2003;3:319-29.
19. Mena P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol
2008;30:100-24.
20. Yavas O, Aytcmir K, Celik I. The prevalence of silent arrhythmia in patients receiving
cisplatin-based chemotherapy.Turkish J of Cancer 2008;38:12-6.
21fTsutsumi T., Ozawa Y, Kawakami A. Acute myocardial infarction induced by lung cancer
chemotherapy with cisplatin and etoposide. Gan To Kagaku Ryoho 1990: 413-7.
22. Rowinsky EK, McGuire WP, Guarieri T. Cardiac disturbances during the administration of
paclitaxel. J Clin Oncol 1991;9:1704-12.
23. Barlesi F, Villani P, Doddoli C. Gemcitabine-induced severe pulmonary toxicity. Fundam
Clin Pharmacol 2004; 18(1 ):85-91.